Clinical Trials
2 trialsNCT05755854 2023-09-22
Allogeneic γ9δ2 T Cells Treatment of Recurrent Hematologic Tumors
Anhui Provincial Hospital
Phase 1 Unknown
NCT01309789 2017-06-28
A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms
Seagen Inc.
Phase 1 Completed